CONCLUSÕES FINAIS
1. Os marcadores imunohistoquímicos p16INK4a e Ki-67 quando presentes em biópsias de colo uterino estão associados a neoplasia maligna.
2. O marcador HLA-G não demonstrou neste estudo correlação com o desenvolvimento de neoplasia de colo de útero.
3. Outros estudos com maior número de pacientes são necessários para se estabelecer quais marcadores devam ser utilizados na prática diária.
REFERÊNCIAS
AERTS, L.; ENZLIN, P.; VERHAEGHE, J.; POPPE, W.; VERGOTE, I.; AMANT, F.
Long-term sexual functioning in women after surgical treatment of cervical cancer stages IA to IB: a prospective controlled study. International Journal of
Gynecological Cancer, v.24, n.8, p.1527-1534, 2014.
AGOFF, S. N.; LIN, P.; MORIHARA, J.; MAO, C.; KIVIAT, N. B.; KOUTSKY, L. A.
p16(INK4a) expression correlates with degree of cervical neoplasia: a comparison with Ki-67 expression and detection of high-risk HPV types. Modern Pathology, v.16, n.7, p.665-673, 2003.
ALBERTS, B.; BRAY, D.; LEWIS, J.; RAFF, M.; ROBERTS, K.; WATSON, J. D.
Molecular Biology of the Cell. New York: Garland Science, 1994.
ANCUŢA, E.; ANCUŢA, C.; COZMA, L. G.; IORDACHE, C.;
ANGHELACHE-LUPAŞCU, I.; ANTON, E.; CARASEVICI, E.; CHIRIEAC, R.Tumor biomarkers in cervical cancer: focus on Ki-67 proliferation factor and E-cadherin expression. Romanian Journal of Morphology and Embryology, v.50, n.3, p.413-418, 2009.
BAAK, J. P.; KRUSE, A. J.; GARLAND, S. M.; SKALAND, I.; JANSSEN, E A.;
TABRIZI, S.; FAGERHEIM, S.; ROBBOY, S.; NILSEN, S. T. Combined p53 and retinoblastoma protein detection identifies persistent and regressive cervical high-grade squamous intraepithelial lesions. The American Journal of Surgical Pathology, v.29, n.8, p1062-1066, 2005.
BARRIER, B. F.; KENDALL, B. S.; SHARPE-TIMMS, K. L.; KOST, E. R. Charac- terization of human leukocyte antigen-G (HLA-G) expression in endometrial adenocarcinoma. Gynecologic Oncology, v.103, n.1, p.25-30, 2006.
BENEVOLO, M.; MOTTOLESE, M.; MARANDINO, F.; VOCATURO, G.; SINDICO, R.;
PIPERNO, G.; MARIANI, L.; SPERDUTI, I.; CANALINI, P.; DONNORSO, R. P.;
VOCATURO, A. Immunohistochemical expression of p16(INK4a) is predictive of HR-HPV infection in cervical low-grade lesions. Modern Pathology, v.19, n.3, p.384-391, 2006.
BOSARI, S.; RONCALLI, M.; VIALE, G.; BOSSI, P.; COGGI, G. p53 immunoreactivity in inflammatory and neoplastic diseases of the uterine cervix. The Journal of Pathology, v.169, n.4, p.425-430, 1993.
BOSCH, F. X.; DE SANJOSÉ, S. The epidemiology of human papillomavirus infection and cervical cancer. Disease Markers, v.23, n.4, p.213-227, 2007.
BOUVARD, V.; BAAN, R.; STRAIF, K.; GROSSE, Y.; SECRETAN, B.; EL
GHISSASSI, F.; BENBRAHIM-TALLAA, L.; GUHA, N.; FREEMAN, C.; GALICHET, L.;
COGLIANO, V; WHO INTERNATIONAL AGENCY FOR RESEARCH ON CANCER MONOGRAPH WORKING GROUP. A review of humans carcinogens- Part B:
biological agents. The Lancet Oncology, v.10, n.4, p.321-322, 2009.
BRAGANÇA, J. F.; DERCHAIN, S. F.; SARIAN, L. O.; MESSIAS DA SILVA, S. M.;
LABATTE, S.; ZEFERINO, L. C. Aided visual inspection with acetic acid (VIA) and HPV detection as optional screening tools for cervical cancer and its precursor lesions.
Clinical and Experimental Obstetrics & Gynecology, v.32, n.4, p.225-229, 2005.
BRENNA, S. M. F. Expressão protéica de p53 e c-myc como marcadores no prognóstico do carcinoma de colo uterino. Revista Brasileira de Ginecologia e Obstetrícia, v.22, n.8, p.529, 2000.
BROWN, C A.; BOGERS, J.; SAHEBALI, S.; DEPUYDT, C. E.; PRINS, F.;
MALINOWSKI, D. P. Role of Protein Biomarkers in the Detection of High-Grade Disease in Cervical Cancer Screening Programs. Journal of Oncology, 2012.
BURCHELL, A. N.; WINER, R. L.; DE SANJOSÉ, S.; FRANCO, E. L. Chapter 6:
Epidemiology and transmission dynamics of genital HPV infection. Vaccine, 24, Suppl 3, p.52-61, 2006.
BURD, E. M. Human Papillomavirus and cervical cancer. Clinical Microbiology Reviews, v.16, n.1, p.1-17, 2003.
CALIL, L. N.; EDELWEISS, M. I.; MEURER, L.; IGANSI, C. N.; BOZZETTI, M. C.
p16INK4a and Ki67 expression in normal, dysplastic and neoplastic uterine cervical epithelium and human papillomavirus (HPV) infection. Pathology, Research and Practice, v.210, n.8, p.482-487, 2014.
CARVALHO, J. J. M. (Ed.).. Atualização em HPV: abordagem científica e multidisciplinar. 2.ed. São Paulo: Instituto Garnet e Hunter Books, 2012.
CASTELLSANGUE, X.; BOSH, F. X.; MUÑOZ, N. Environmental co-factors in HPV carcinogenesis. Virus Research, v.89, n.2, p.191-199, 2002.
CERVICAL CANCER SCREENING IN THE NETHERLANDS. Disponível em:
<www.genomeweb.com/pcr/netherlands-awards-roche-contract-cervical-cancer-scre ening-program-using-cobas-hpv-assay>. Acesso em 16 fev. 2016.
CHAN, A. B.; FOX, J. D. NASBA and other transcription-based amplification methods for research and diagnostic microbiology. Reviews in Medical Microbiology, v.10, p.184-196, 1999.
CHEN, Q. M.; LUO, G.; LI, B. Q.; SAMARANAYAKE, L. P. Expression of p16 and CDK4 in oral premalignant lesions and oral squamous cell carcinoma: a
semi-quantitative immunohistochemical study. Journal of Oral Pathology &
Medicine, v.28, n.4, p.158-164, 1999.
CLIFFORD, G. M.; SMITH, J. S.; PLUMMER, M.; MUÑOZ, N.; FRANCESCHI, S.
Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis.
British Journal of Cancer, v.88, n.1, p.63-73, 2003.
COLLINS, K.; JACKS, T.; PAVLETICH, N. P. The cell cycle and cancer. Proceedings of the National Academy of Sciences, v.94, n.7, p.2776-2778, 1997.
CUZICK, J.; CLAVEL, C.; PETRY, K. U.; MEIJER, C. J.; HOYER, H.; RATNAM, S.;
SZAREWSKI, A.; BIREMBAUT, P.; KULASINGAM, S.; SASIENI, P.; IFTNER, T.
Overwiew of the European and North American studies on HPV testing in primary cervical cancer screening. International Journal of Cancer, v.119, n.5, p.1095-1101, 2006.
DENNY, L. The prevention of cervical cancer in developing countries. BJOG, v.112.
n.9, p.1204-1212, 2005.
DEXEUS, S.; CARARACH, M.; DEXEUS, D. The role of colposcopy in modern
gynecology. European Journal of Gynaecological Oncology, v.23, n.4, p.269-277, 2002.
DIDELOT-ROUSSEAU, M. N.; NAGOT, N.; COSTES-MARTINEAU, V.; VALLÈS, X.;
OUEDRAOGO, A.; KONATE, I.; WEISS, H. A.; VAN DE PERRE, P.; MAYAUD, P.;
SEGONDY, M.; YERELON STUDY GROUP. Human papillomavirus genotype
distribution and cervical squamous intraepithelial lesions among high-risk women with and without HIV-1 infection in Burkina Faso. British Journal of Cancer, v.95, n.3, p.355-362, 2006.
DITTO, A.; MARTINELLI, F.; BOGANI, G.; FISCHETTI, M.; DONATO, V.; LORUSSO, D.;
RASPAGLIESI, F. Fertility-Sparing Surgery in Early-Stage Cervical Cancer Patients Oncologic and Reproductive Outcomes. International Journal of Gynecological Cancer, v.25, n.3, p.493-497, 2015.
DONG, D. D.; YANG, H.; LI, K.; XU, G.; SONG, L. H.; FAN, X. L.; JIANG, X. L.; YIE, S.
M. Human leu- kocyte antigen-G (HLA-G) expression in cervical lesions: association with cancer progression, HPV 16/18 infection, and host immune response.
Reproductive Sciences, v.17, n.8, p.718-723, 2010.
DRAY, M.; RUSSELL, P.; DALRYMPLE, C.; WALLMAN, N.; ANGUS, G.; LEONG, A.;
CARTER, J.; CHEERALA, B. p16(INK4a) as a complementary marker of high-grade intraepithelial lesions of the uterine cervix. I: Experience with squamous lesions in 189 consecutive cervical biopsies. Pathology, v.37, n.2, p.112-124, 2005.
DUENSING S, MUNGER K. Centrosome abnormalities, genomic instability and carcinogenic progression. Biochim Bophys Acta, v.1471, n.2, p.M81-88, 2001.
EILEEN, M. B. Human Papillomavirus and Cancer Cervical. Clinical Microbiology Reviews, v.16, n.1, p.1-17, 2003.
FINLAY, C. A.; HINDS, P. W.; TAN, T. H.; ELIYAHU, D.; OREN, M.; LEVINE, A. J.
Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life. Molecular and Cellular Biology, v.8, n.2, p.531-539, 1988.
FLANNELLY, G.; BOLGER, B.; FAWZI, H.; DE LOPES, A. B.; MONAGHAN, J. M.
Follow up after LLETZ: could schedules be modified according to risk of recurrence?
BJOG, v.108, p.1025-1030, 2001.
FONATSCH, C.; DUCHROW, M.; RIEDER, H.; SCHLÜTER, C.; GERDES, J.
Assignment of the human Ki-67 gene (MK167) to 10q25-qter. Genomics, v.11, n.2, p.476-477, 1991.
FREITAS, A. C.; COIMBRA, E. C.; LEITÃO, M. C. G. Molecular targets of HPV oncoproteins: Potential biomarkers for cervical carcinogenesis. Biochim Biophys Acta, v.1845, n.2, p.91-103, 2014.
FRØDING, L. P.; OTTOSEN, C.; MOSGAARD, B. J; JENSEN, P. T.Quality of Life, Urogynecological Morbidity, and Lymphedema After Radical Vaginal Trachelectomy for Early-Stage Cervical Cancer. International Journal of Gynecological Cancer, v.25, n.4, p.699-706, 2015.
GARCIA-LORA, A.; ALGARRA, I.; GARRIDO, F. MHC class I antigens, immune surveillance, and tumor immune escape. Journal of Cellular Physiology, v.195, n.3, p.346-355, 2003.
GONCALVES, M. A.; LE DISCORDE, M.; SIMOES, R. T.; RABREAU, M.;
SOARES, E. G.; DONADI, E. A.; CAROSELLA, E. D. Classical and non-classical HLA molecules and p16(INK4a) expression in precursors lesions and invasive cervical cancer. European Journal of Obstetrics, Gynecology, and Reproductive Biology, v.141, n.1, p.70-74, 2008.
GONTIJO, R. C.; DERCHAIN, S. F.; ROTELI-MARTINS, C.; BRAGANÇA, J. F.;
SARIAN, L. O.; MORAIS, S. S.; MAEDA, M. Y.; LONGATTO-FILHO, A.;
SYRJÄNEN, K. J. Human papillomavirus (HPV) infections as risk factors for cytological and histological abnormalities in baseline PAP smear-negative women followed-up for 2 years in the LAMS study. European Journal of Obstetrics & Gynecology and Reproductive Biology, v.133, n.2, p.239-246, 2007.
GRIMM, D.; HASENBURG, A.; EULENBURG, C.; STEINSIEK, L.; MAYER, S.;
ELTROP, S.; PRIESKE, K.; TRILLSCH, F.; MAHNER, S.; WOELBER, L. Sexual Activity and Function in Patients With Gynecological Malignancies After Completed Treatment. International Journal of Gynecological Cancer, v.25, n.6, p.1134-1141, 2015.
GUIMARÃES, M. C.; SOARES, C. P.; DONADI, E. A.; DERCHAIN, S. F.;
ANDRADE, L. A.; SILVA, T. G.; HASSUMI, M. K.; SIMÕES, R. T.; MIRANDA, F. A.;
LIRA, R. C.; CRISPIM, J.; SOARES, E. G.Low expression of human histocompatibility soluble leukocyte antigen-G (HLA-G5) in invasive cervical cancer with and without metastasis, associated with papilloma virus (HPV). The Journal of Histochemistry and Cytochemistry, v.58, n.5, p.405-411, 2010.
GUSTINUCCI, D.; GIORGI ROSSI, P.; CESARINI, E.; BROCCOLINI, M.; BULLETTI, S.;
CARLANI, A.; D'ANGELO, V.; D'AMICO, M. R.; DI DATO, E.; GALEAZZI, P.;
MALASPINA, M.; MARTINELLI, N.; SPITA, N.; TINTORI, B.; GIAIMO, M. D.;
PASSAMONTI, B. Use of Cytology, E6/E7 mRNA, and p16INK4a- Ki-67 to Define the Management of Human Papillomavirus (HPV) Positive Women in Cervical Cancer Screening. American Journal of Clinical Pathology, v.145, n.1, p.35-45, 2016.
HANPRASERTPONG, J.; TUNGSINMUNKONG, K.; CHICHAREON, S.;
WOOTIPOOM, V.; GEATER, A.; BUHACHAT, R.; BOONYAPIPAT, S. Correlation of p53 and Ki-67 (MIB-1) expressions with clinicopathological features and prognosis of early stage cervical squamous cell carcinomas. Journal of Obstetrics and
Gynaecology Research, v.36, n.3, p.572-580, 2010.
HOULARD, S.; PERROTIN, F.; FOURQUET, F.; MARRET, H.; LANSAC, J.; BODY, G.
Risk factors for cervical stenosis after laser cone biopsy. European Journal of Obstetrics & Gynecology and Reproductive Biology, v.104, n.2, p.144-147, 2002.
HUANG, M. Z.; HUANG, S.; LI, D. Q.; NIE, X. M.; LI, H. B.; JIANG, X. M. The study of the combi- nation detection of HPV-DNA and p16INK4a in cervical Lesions. Medical Oncology, v.28, p.S547-S552, 2011.
HUNG, M. C.; WU, C. L.; HSU, Y. Y.; HWANG, J. S.; CHENG, Y. M.; WANG, J. D Estimation of Potential Gain in Quality of Life from Early Detection of Cervical Cancer.
Value in Health, v.17, n.4, p.482-486, 2014.
INFORMATION CENTER ON HPV AND CANCER (ICO). Disponível em:
<www.hpvcentre.net>. Acesso em: 23 dez. 2015.
INSTITUTO NACIONAL DO CÂNCER (INCA). Incidência de câncer no Brasil:
estimativa 2016. Disponível em: <
http://www.inca.gov.br/wcm/dncc/2015/por-tipos.asp >. Acesso em: 10 fev. 2016.
KALOF, A. N.; COOPER, K. p16INK4a immunoexpression: surrogate marker of high- risk HPV and high-grade cervical intraepithelial neoplasia. Advances in Anatomic Pathology, v.13, n.4, p.190-194, 2006.
KALOF, A. N.; EVANS, M. F.; SIMMONS-ARNOLD, L.; BEATTY, B. G.; COOPER, K.
p16INK4A immunoexpression and HPV in situ hybridization signal patterns: potential markers of high-grade cervical intraepithelial neoplasia. The American Journal of Surgical Pathology, v.29, n.5, p.674-679, 2005.
KITCHENER, H. C.; CASTLE, P. E.; COX, J. T. Chapter 7: Achievements and limitations of cervical cytology screening. Vaccine, v.3, p.63-70, 2006.
KJAER, S. K.; DEN BRULE, J. C.; PAULL, G.; SVARE, E. I.; SHERMAN, M. E.;
THOMSEN, H. L.; SUNTUM, M.; BOCK, J. E.; POLL, P. A.; MEIJER, C. J. Type specific persistence of high risk human papillomavirus (HPV) as indicator of high grade cervical squamous intraepithelial lesions in young women: population based
prospective follow up study. British Medical Journal, v.325, p.1-7, 2002.
KOLIOPOULOS, G.; ARBYN, M.; MARTIN-HIRSCH, P.; KYRGIOU, M.;
PRENDIVILLE, W.; PARASKEVAIDIS, E. Diagnostic accuracy of human papillomavirus testing in primary cervical screening: a systematic review and meta-analysis of non-randomized studies. Gynecologic Oncologogy, v.104, n.1, p.232-246, 2007.
KRUSE, A. J.; BUHR‐WILDHAGEN, S.; JANSSEN, E. A.; BAAK, J. P. The relationship between syntactic structure analysis features, histological grade and high‐risk HPV DNA in cervical intraepithelial neoplasia. Cellular Oncology, v.26, n.3, p.135-141, 2004.
LAPIN, G. A.; DERCHAIN, S. F.; TAMBASCIA, J. Comparação entre a colpocitologia oncológica de encaminhamento e a da gravidade das lesões cervicais intra- epiteliais.
Revista de Saúde Pública, v.34, n.2, p.120-125, 2000.
LEFEBVRE, S.; ANTOINE, M.; UZAN, S.; MCMASTER, M.; DAUSSET, J.;
CAROSELLA, E. D.; PAUL, P. Specific activation of the non-classical class I
histocompatibility HLA-G antigen and expression of the ILT2 in- hibitory receptor in human breast cancer. The Journal of Pathology, v.196, n.3, p.266-274, 2002
LESNIKOVA, I.; LIDANG, M.; HAMILTON-DUTOIT, S.; KOCH, J. p16 as a diagnostic marker of cervical neoplasia: a tissue microarray study of 796 archival specimens.
Diagnostic Pathology, v.4, p.22, 2009.
LI, T.; HUANG, H.; LIAO, D.; LING, H.; SU, B.; CAI, M. Genetic polymorphism in HLA-G 3'UTR 14-bp ins/del and risk of cancer: a meta-analysis of case-control study.
Molecular Genetics and Genomics, v.290, n.4, p.1235-1245, 2015.
LI, X. J.; ZHANG, X.; LIN, A.; RUAN, Y. Y.; YAN, W. H. Human leukocyte antigen-G (HLA-G) expression in cervical câncer lesions is asociated with disease progression.
Human immunology, v.73, p.946-949, 2012.
LIE, A. K.; RISBERG, B.; BORGE, B.; SANDSTAD, B.; DELABIE, J.; RIMALA, R.;
ONSRUD, M.; THORESEN, S. DNA- versus RNA-based methods for human papillomavirus detection in cervical neoplasia. Gynecologic Oncology, v.97, n.3, p.908-915, 2005.
LIN, C. T.; TSENG, C. J.; LAI, C. H.; HSUEH, S.; HUANG, K. G.; HUANG, H. J.;
CHAO, A. Value of human papillomavirus deoxyribonucleic acid testing after conization in the prediction of residual disease in the subsequent hysterectomy specimen.
American Journal of Obstetrics and Gynecology, v.184, n.5, p.940-955, 2001.
LIZANO, M.; BERUMEN, J.; GARRANCÁ, G. A. HPV-related carcinogenesis: basic concepts, viral types and variants. Archives of Medical Research, v.40, n.6, p.428-434, 2009.
LONGATTO-FILHO, A.; ERZEN, M.; BRANCA, M.; ROTELI-MARTINS, C.; NAUD, P.;
DERCHAIN, S. F.; HAMMES, L.; SARIAN, L. O.; BRAGANÇA, J. F.; MATOS, J.;
GONTIJO, R.; LIMA, T.; MAEDA, M. Y.; TATTI, S.; SYRJÄNEN, S.; DORES, G.;
LÖRINCZ, A.; SYRJÄNEN, K. Human papillomavirus testing as an optional screening tool in low-resource settings of Latin America: experience from the Latin American Screening study. International Journal of Gynecological Cancer, v.16, n.3, p.955-962, 2006.
LOWNDES, C. M. Vaccines for cervical cancer. Epidemiology and Infection, v.134, n.1, p.1-12, 2006.
MARTIN, C. M.; O'LEARY, J. J.Histology of cervical intraepithelial neoplasia and the role of biomarkers. Best Practice & Research Clinical Obstetrics and Gynecology, v.25, n.5, p.605-615, 2011.
MASSAD, S. L.; EINSTEIN, M. H.; HUH, W. K.; KATKI, H. A.; KINNEY, W. K.;
SCHIFFMAN, M.; SOLOMON, D.; WENTZENSEN, N.; LAWSON, H. W. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. Journal of Lower Genital Tract Disease, v.17, n.5,
p.S1-S27, 2013.
McCLUGGAGE WG. Immunohistochemical and functional biomarkers of value in female genital tract lesions. International Journal of Gynecological Pathology, v.25, n.2, p.101-120, 2006.
METCALFE, S.; ROGER, M.; FAUCHER, M. C.; COUTLEìE, F.; FRANCO, E. L.;
BRASSARD, P. The association between human leukocyte antigen (HLA)-G
polymorphisms and human papillomavirus (HPV) infection in Inuit women of northern Quebec. Human Immunology, v.74, p.1610-1615, 2013.
MIMICA, M.; TOMICì, S.; KARDUM, G.; HOFMAN, I. D.; KALITERNA, V.; PEJKOVICì, L. Ki-67 quantitative evaluation as a marker of cervical intraepithelial neoplasia and human papillomavirus infection. International Journal of Gynecological Cancer, v.20, n.1, p.116-119, 2010.
MOLDEN, T.; KRAUS, I.; KARLSEN, F.; SKOMEDAL, H.; HAGMAR, B. Human papillomavirus E6/E7 mRNA expression in women younger than 30 years of age.
Gynecologic Oncology, v.100, n.1, p.95-100, 2006.
MOODY, C. A.; LAIMINS, L. A. Human papillomavirus oncoproteins: pathways to transformation. Nature Reviews, v.10, n.8, p.550-560, 2010.
MOSCICKI, A. B.; HILLS, N.; SHIBOSKI, S.; POWELL, K.; JAY, N.; HANSON, E.;
MILLER, S.; CLAYTON, L.; FARHAT, S.; BROERING, J.; DARRAGH, T.; PALEFSKY, J.
Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females. Journal of the American Medical Association, v.285, n.23, p.2995, 2001.
MOSCICKI, A. B.; MA, Y.; WIBBELSMAN, C.; DARRAGH, T. M.; POWERS, A.;
FARHAT, S.; SHIBOSKI, S. Rate of and Risks for Regression of CIN-2 in adolescents and young women. Obstetrics & Gynecology, v.116, n.6, p.1373-1380, 2010.
MÜNGER, K.; BALDWIN, A.; EDWARDS, K. M.; HAYAKAWA, H.; NGUYEN, C. L.;
OWENS, M.; GRACE, M.; HUH, K. Mechanisms of human papillomavirus-induced oncogenesis. Journal of Virology, v.78, n.21, p.11451-1160, 2004.
MUÑOZ, N.; BOSCH, F. X.; DE SANJOSÉ, S.; HERRERO, R.; CASTELLSAGUÉ, X.;
SHAH, K. V.; SNIJDERS, P. J.; MEIJER, C. J.; INTERNATIONAL AGENCY FOR RESEARCH ON CANCER MULTICENTER CERVICAL CANCER STUDY GROUP.
Epidemiologic classification of human papillomavirus types associated with cervical cancer. New England Journal of Medicine, v.348, n.6, p.518-527, 2003.
NAM, E. J.; KIM, J. W.; HONG, J. W.; JANG, H. S.; LEE, S. Y.; JANG, S. Y.; LEE, D.
W.; KIM SW.; KIM, J. H.; KIM, Y. T.; KIM, S.; KIM, J. W. Expression of the p16INK4a and Ki-67 in relation to the grade of cervical intraepithelial neoplasia and high-risk human papillomavirus infection. Journal of Gynecologic Oncology, v.19, n.3, p.162-168, 2008.
NARISAWA-SAITO, M.; KIYONO, T. Basic mechanism of high-risk human
papillomavirus-induced carcinogenesis: roles of E6 and E7 proteins. Cancer Science, v.98, n.10, p.1505-1511, 2007.
NATIONAL CANCER INSTITUTE. SEER Data: Surveillance, Epidemiology And End Results. Disponível em: <http://seer.cancer.gov/statfacts/html/cervix.html>. Acesso em: 25 jan. 2015.
NATIONAL CERVICAL SCREENING PROGRAM. Disponível em:
<http://www.cancerscreening.gov.au/internet/screening/publishing.nsf/content/cervica l-screening-1>. Acesso em: 14 fev. 2016.
NIELSEN, G. P.; STEMMER-RACHAMIMOV, A. O.; SHAW, J.; ROY, J. E.; KOH, J.;
LOUIS, D. N. Immunohistochemical survey of p16INK4A expression in normal human adult and infant tissues. Laboratory Investigation, v.79, n.9, p.1137-1143, 1999.
OLIVEIRA, A. E. C.; DEININGER, L. S. C.; LUCENA, K. D. T. The viewpoint of women on cutological cervical uterine examination. Revista de Enfermagem UFPE, Recife, v.8, n.1, p.p.90-97, 2014
O'NEILL, C. J.; McCLUGGAGE, W. G. p16 expression in the female genital tract and its value in diagnosis. Advances in Anatomic Pathology, v.13, n.1, p.8-15, 2006.
ORDI, J.; SAGASTA, A.; MUNMANY, M.; RODRÍGUEZ-CARUNCHIO, L.; TORNÉ, A.;
DEL PINO, M. Usefulness of p16/Ki67 immunostaining in the triage of women referred to colposcopy. Cancer Cytopathology, v.122, n.3, p.227-235, 2014.
ÖSTOR, A. G. The natural history of cervical intraepithelial neoplasia: a critical review.
International Journal of Gynecological Pathology, v.12, p.186-192, 1993.
PANATTO, D.; AMICIZIA, D.; TRUCCHI, C.; CASABONA, F.; LAI, P. L.; BONANNI, P.;
BONANNI, P.; BOCCALINI, S.; BECHINI, A.; TISCIONE, E.; ZOTTI, C. M.;
COPPOLA, R. C.; MASIA, G.; MELONI, A.; CASTIGLIA, P.; PIANA, A.; GASPARINI, R.
Sexual behavior and risk factors for the acquisition of human papillomavirus infections in young people in Italy: suggestions for future vaccination policies. BMC Public Health, v.12, n.1, p.623, 2012.
PANJKOVIC, M.; IVKOVIC-KAPICL, T. Ki-67 expression in squamous intraepithelial lesions of the uterine cervix. Archive of Oncology, v.14, p.23-25, 2006.
PARK, J. Y.; LEE, S. M.; YOO, C. W.; KANG, S.; PARK, S. Y.; SEO, S. S. Risk factors predicting residual disease in subsequent hysterectomy following conization for cervical intraepithelial neoplasia (CIN) III and microinvasive cervical cancer. Gynecologic Oncology, v.107, n.1, p.39-44, 2007.
PARKIN, D.M. The global health burden of infection-associated cancers in the year.
International Journal of Cancer, v.118, n.2, p.3030-3044, 2006.
PENNA, C.; FAMBRINI, M.; FALLANI, MG.; PIERALLI, A.; SCARSELLI, G.;
MARCHIONNI, M. Laser CO2 conization in postmenopausal age: risk of cervical stenosis and unsatisfactory follow-up. Gynecologic Oncology, v.96, p.771-775, 2005.
PINTO, A. P.; DEGEN, M.; VILLA, L. L.; CIBAS, E. S. Immunomarkers in gynecologic cytology: the search for the ideal biomolecular papanicolaou test. Acta Cytologica, v.56, n.2, p.109-121, 2012.
PLUMMER, M.; SCHIFFMAN, M.; CASTLE, P. E.; MAUCORT-BOULCH, D.;
WHEELER, C. M. A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion. The Journal of Infectious Diseases, v.195, n.11, p.1582-1589, 2007.
PRUNOIU, V. M.; MARINCAŞ, M. A.; CIRIMBEI, C.; IONESCU, S.; ZURAC, S.;
RADU, M.; NICOLAESCU, R.; BRĂTUCU, E.; STRAJA, N. D. The configuration of biomolecular markers in cancer of the uterine cervix. Personalized therapy. Monitoring andprognosis. Chirurgia (Bucur), v.110, n.2, p.144-150, 2015.
QUEIROZ, C.; SILVA, T. C.; ALVES, V. A.; VILLA, L. L.; COSTA, M. C.; TRAVASSOS, A. G.; FILHO, J. B.; STUDART, E.; CHETO, T.; DE FREITAS, L. A. Comparative study of the expression of cellular cycle proteins in cervical intraepithelial lesions. Pathology, Research and Practice, v.202, n.10, p.731-737, 2006.
REUSCHENBACH, M.; SEIZ, M.; DOEBERITZETAL, C. V. K. Evaluation of cervical cone biopsies for coexpression of p16INK4a and Ki- 67 in epithelial cells. International Journal of Cancer, v.130, n.2, p.388-394, 2012.
RICHART, R. M. Natural history of cervical intraepithelial neoplasia. Clinical Obstetrics & Gynaecology, v.5, p.748-794, 1968.
ROCCO, J. W.; SIDRANSKY, D. p16 (MTS-1/CDKN2/INK4a) in cancer progression.
Experimental Cell Research, v.264, n1, p.42-55, 2001.
SARI ASLANI, F.; SAFAEI, A.; POURJABALI, M.; MOMTAHAN, M. Evaluation of Ki67, p16 and CK17 Markers in Differentiating Cervical Intraepithelial Neoplasia and Benign Lesions. Iranian Journal of Medical Sciences, v.38, n.1, p.15-21, 2013.
SARIAN, L. O.; DERCHAIN, S. F.; PITTA, D. R.; ANDRADE, L. A.; MORAIS, S. S.;
FIGUEIREDO, P. G. Human papillomavirus detection by hybrid capture II and residual or recurrent high-grade squamous cervical intraepithelial neoplasia after large loop excision of the transformation zone (LLETZ). Tumori, v.91, n.2, p.188-192, 2005.
SCHEFFNER, M.; MÜNGER, K.; BYRNE, J. C.; HOWLEY, P. M. The state of the p53 and retinoblastoma genes in human cervical carcinoma cell lines. Proceedings of the National Academy of Sciences of the United States of America, v.88, n.13,
p.5523-5527, 1991.
SCHMIDT, D. C.; BERGERON, C.; DENTON, K. J.; RIDDER, R. “p16/ki-67 dual-stain cytology in the triage of ASCUS and LSIL papanicolaou cytology: results from the European equivocal or mildly abnormal papanicolaou cytology study”. Cancer Cytopathology, v.119, n.3, p.158-166, 2011.
SELINKA, H. C.; SOTLAR, K.; KLINGEL, K.; SAUTER, M.; KANDOLF, R.;
BULTMANN, B. Detection of human papillomavirus 16 transcriptional activity in cervical intraepithelial neoplasia grade III lesions and cervical carcinomas by nested reverse transcription-polymerase chain reaction and in situ hybridization. Laboratory Investigation, v.78, n.1, p.9-18, 1998.
SHEU, J. J.; SHIH, I. M. Clinical and biological significance of HLA- G expression in ovarian cancer. Seminars in Cancer Biology, v.17, n.6, p.436-443, 2007.
SHEU, J.; SHIH, IeM. HLA-G and immune evasion in cancer cells. Journal of the Formosan Medical Association, v.109, p.248, 2010.
SIEGEL, R.; NAISHADHAM, D.; JEMAL, A. Cancer statistics, 2013. CA: A Cancer Journal for Clinicians, v.63, n.1, p.11-30, 2013.
SILVA, I. D.; MUNIZ, Y. C. N.;MILLENA SOUSA, M. C. P. S.; SILVA, K. R.;
CASTELLI, E. C.; FILHO, J. C. G.;OSTA, A.P.; LIMA, M. I. M.; SIMÕES, R. T. HLA-G 30UTR polymorphisms in high grade and invasive cervico-vaginal cancer. Human Immunology, v.74, p.452-458, 2013.
SINGH, C.; MANIVEL, C.; TRUSKINOVSKY, A. M.; SAVIK, K.; AMIROUCHE, S.;
HOLLER, J.; THYAGARAJAN, B.; GULBACHE, E.; PAMBUCCIAN, S. E. Variability of phatologyst' utilization of p16 and Ki-67 immunostaining in the diagnosis of cervical biopsies in routine pathology practice and its impacto n the frequencies of cervical intraepithelial neoplasia diagnoses and cytohistologic correlations.Archives of Pathology & Laboratory Medicine, v.138, 2014.
SKAPA, P.; ROBOVA, H.; ROB, L.; ZAMECNIK, J. p16INK4a Immunoprofiles of Squamous Lesions of Uterine Cervix-Implications for the Reclassification of Atypical Immature Squamous Metaplasia. PathologyOncology Research, v.19, p.707-714, 2013.
SMITH, J. S.; LINDSAY, L.; HOOTS, B.; KEYS, J.; FRANCESCHI, S.; WINER, R.;
CLIFFORD, G. M. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. International Journal of Cancer, v.121, n.3, p.621-632, 2007.
SOLOMON, D.; DAVEY, D.; KURMAN, R.; MORIARTY, A.; O'CONNOR, D.; PREY, M.; RAAB, S.; SHERMAN, M.; WILBUR, D.; WRIGHT, T. JR.; YOUNG, N; FORUM GROUP MEMBERS; BETHESDA 2001 WORKSHOP. The 2001 Bethesda System:
terminology for reporting results of cervical cytology. JAMA, v.287, n.16, p.2114-2119, 2002.
SPITZER, M.; APGAR, B. S.; BROTZMAN, G. L. Management of histologic
abnormalities of the cervix. American Family Physician, v.73, n.1, p.105-112, 2006.
SPRACKLEN, C. N.; HARLAND, K. K.; STEGMANN, B. J.; SAFTLAS, A. F. Cervical surgery for cervical intraepithelial neoplasia and prolonged time to conception of a live birth: a case-control study. BJOG: An International Journal of Obstetrics &
Gynaecology, v.120, n.8, p.960-965, 2013.
SRINIVAS, P. R.; KRAMER, B. S.; SRIVASTAVA, S. Trends in biomarker research for cancer detection. The Lancet Oncology, v.2, n.11, p.698-704, 2001.
STANLEY, M. Genital human papillomavirus infection-current and prospectivetherapies.
Journal of the National Cancer Institute Monographs, v.31, p.117-124, 2003.
SYRJÄNEN, K.; NAUD, P.; DERCHAIN, S.; ROTELI-MARTINS, C.; LONGATTO-FILHO, A.; TATTI, S.; BRANCA, M.; ERZEN, M.; HAMMES, L. S.; MATOS, J.; GONTIJO, R.; SARIAN, L.; BRAGANCA, J.; ARLINDO, F. C.; MAEDA, M. Y.; LÖRINCZ,
A.; DORES, G. B.; COSTA, S.; SYRJÄNEN, S. Comparing PAP smear cytology, aided visual inspection, screening colposcopy, cervicography and HPV testing as optional screening tools in Latin America. Study design and baseline data of the LAMS study.
Anticancer Research, v.25, n.5, p.3469-3480, 2005.
SYRJANEN, S. M.; SYRJANEN, K. J. New concepts on the role of human
papillomavirus in cell cycle regulation. Annals of Medicine, v.31, n.3, p.175-187, 1999.
TERMINI, L.; VILLA, L. L. Biomarkers in cervical cancer screening. DST – Jornal Brasileiro de Doenças Sexualmente Transmissíveis, v.20, n.2, p.125-131, 2008
TORNESELLO, M. L.; BUONAGURO, L.; GIORGI-ROSSI, P.; BUONAGURO, F. M.
Viral and cellular biomarkers in the diagnosis of cervical intraepithelial neoplasia and cancer. BioMed Research Internacional, p.1-10, 2013.
TSOUMPOU, I.; ARBYN, M.; KYRGIOU, M.;WENTZENSEN, N.;KOLIOPOULOS, G.;
MARTIN-HIRSCH, P.; MALAMOU-MITSI, V.; PARASKEVAIDIS, E. p16INK4a immunostaining in cytological and histological specimens from the uterine cervix: A systematic review and meta-analysis. Cancer Treatment Reviews, v.35, n.3, p.210-220, 2009.
VASSALLO, J.; DERCHAIN, S. F.; PINTO, G. A.; MARTINEZ, E. Z.; SYRJÄNEN, K. J.;
ANDRADE, L. A. High risk HPV and p53 protein expression in cervical intraepithelial neoplasia. International Journal of Gynaecology and Obstetrics, v.71, n.1, p.45-48, 2000.
VERMEULEN, C. F.; JORDANOVA, E. S.; ZOMERDIJK-NOOIJEN, Y. A.; TER HAAR, N. T.; PETERS, A. A.; FLEUREN, G. J. Frequent HLA class I loss is an early event in cervical carcinogenesis. Human Immunology, v.66, n.11, p.1167-1173, 2005.
VICUS, D.; SUTRADHAR, R.; LU, Y.; KUPETS, R.; PASZAT, L. Ontario Cancer Screening Research Network. Association between cervical screening and prevention of invasive cervical cancer in Ontario: a population-based case-control study.
International Journal of Gynecological Cancer, v.25, n.1, p.106-111, 2015.
WACHOLDER, S. Chapter 18: Statistical issues in the design and analysis of studies of human papillomavirus and cervical neoplasia. Journal of the National Cancer Institute. Monographs, n.31, p.125-130, 2003.
WENTZENSEN, N.; VINOKUROVA, S.; VON KNEBEL DOEBERITZ, M. Systematic
WENTZENSEN, N.; VINOKUROVA, S.; VON KNEBEL DOEBERITZ, M. Systematic